Mixed Reality and AI to aid surgeons with keyhole heart valve surgery
Cardiac surgeons could in the future be conducting procedures virtually before even stepping into an operating theatre thanks to researchers from the University of West of England who are working with cardiac surgeons from the University of Bristol on new technology that will allow surgeons to better predict risks and help prevent the conversion of a keyhole heart valve operation to open heart surgery. (Source: University of Bristol news)
Source: University of Bristol news - January 24, 2022 Category: Universities & Medical Training Tags: Health, Research; Institutes, Bristol Heart Institute, Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news
Mayo Clinic Healthcare in London expands advanced cardiac imaging services
LONDON — Mayo Clinic Healthcare in London has expanded its slate of advanced cardiac imaging tools to include 3D transoesophageal echocardiography. The addition supports full diagnostics for heart valve diseases, with assessments and review by Mayo Clinic Healthcare experts in the UK and their colleagues in the U.S. This transoesophageal echo image shows a bicuspid aortic valve with evidence of mild regurgitation, or leaking. Source: Mayo Clinic Healthcare. Transoesophageal echo is a state-of-the-art imaging assessment… (Source: Mayo Clinic Business News)
Source: Mayo Clinic Business News - January 24, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Okays Sapien 3 Heart Valve With Alterra Adaptive Prestent FDA Okays Sapien 3 Heart Valve With Alterra Adaptive Prestent
Edwards Lifesciences says the pulmonic valve replacement system will expand transcatheter treatment options for congenital heart disease patients.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 20, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
ECG Challenge: In the ED With Palpitations, Shortness of Breath ECG Challenge: In the ED With Palpitations, Shortness of Breath
A 67-year-old with controlled hypertension and heart valve disease visits the ED with intermittent palpitations and trouble breathing. What ' s going on?theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 30, 2021 Category: Cardiology Tags: Cardiology Clinical Case Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Scientists Successfully Attached a Pig Kidney to Human For the First Time
Scientists temporarily attached a pig’s kidney to a human body and watched it begin to work, a small step in the decades-long quest to one day use animal organs for life-saving transplants.
Pigs have been the most recent research focus to address the organ shortage, but among the hurdles: A sugar in pig cells, foreign to the human body, causes immediate organ rejection. The kidney for this experiment came from a gene-edited animal, engineered to eliminate that sugar and avoid an immune system attack.
Surgeons attached the pig kidney to a pair of large blood vessels outside the body of a deceased recipient so they cou...
Source: TIME: Health - October 20, 2021 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Research wire Source Type: news
Scientists Successfully Attached a Pig Kidney to Human For the First Time
Scientists temporarily attached a pig’s kidney to a human body and watched it begin to work, a small step in the decades-long quest to one day use animal organs for life-saving transplants.
Pigs have been the most recent research focus to address the organ shortage, but among the hurdles: A sugar in pig cells, foreign to the human body, causes immediate organ rejection. The kidney for this experiment came from a gene-edited animal, engineered to eliminate that sugar and avoid an immune system attack.
Surgeons attached the pig kidney to a pair of large blood vessels outside the body of a deceased recipient so they cou...
Source: TIME: Science - October 20, 2021 Category: Science Authors: Carla K. Johnson / AP Tags: Uncategorized Research wire Source Type: news
Open Stent Solution closes 2.5M Seed financing round for its breakthrough open-stent TMVR device
AMIENS, France, Sept. 28, 2021 -- (Healthcare Sales & Marketing Network) -- Open Stent Solution (OSS), a medtech start-up company developing the first open-stent heart valves, today announced the closing of a 2.5 million Seed financing round. The funding... Devices, Interventional, Cardiology, Venture Capital Open Stent Solution, open-stent heart valves, OSS valve, mitral valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2021 Category: Pharmaceuticals Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Abbott's Epic ™ Plus Tissue Valves for People in Need of Mitral or Aortic Valve Replacement
- New enhancements to Abbott's Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures (Source: Abbott.com)
Source: Abbott.com - September 22, 2021 Category: Pharmaceuticals Source Type: news
Mom-to-Be's'Leaky' Heart Valves May Pose More Danger Than Thought
THURSDAY, Sept. 9, 2021 -- Leaky heart valves can put pregnant women at serious risk, according to a large study that runs counter to established practice.
The condition used to be considered relatively harmless during pregnancy. But this analysis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2021 Category: General Medicine Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
NHS Improvement National Patient Safety Alert: Inappropriate anticoagulation of patients with a mechanical heart valve
NHS Improvement has published details of a National Patient Safety Alert around inappropriate anticoagulation of patients with a mechanical heart valve.
Incidents have been reported of patients with (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - July 14, 2021 Category: Drugs & Pharmacology Source Type: news
